['type 1 diabetes mellitus']
['sotagliflozin', 'sotagliflozin', 'placebo']

        Inclusion Criteria:

          -  Participant who gave written informed consent to participate in the study in
             accordance with local regulations.

          -  Adult participants 18 years and older with a diagnosis of T1D made at least 1 year
             prior to informed consent.

          -  Participants treated with insulin or insulin analog delivered via continuous
             subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

          -  Willing and were able to perform Self-monitoring of blood glucose (SMBG) and completed
             the study diary as required per protocol.

          -  At the Screening Visit, A1C was between 7.0% to 11.0%.

          -  Females of childbearing potential must use an adequate method of contraception and
             have a negative pregnancy test.

        Exclusion Criteria:

          -  Use of antidiabetic agent other than insulin or insulin analog at the time of
             screening.

          -  Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to
             screening.

          -  Chronic systemic corticosteroid use.

          -  Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the
             Investigator.
      